Diabetes mellitus and abdominal aortic aneurysms: A review of the mechanisms underlying the negative relationship

Diabetes and Vascular Disease Research

Volumn 15, Issue 5, 2018, Pages 367-374

  Dattani, Nikesh ^a   Sayers, Robert D ^a   Bown, Matthew J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Abdominal aortic aneurysm; diabetes mellitus; hyperglycaemia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; MATRIX METALLOPROTEINASE; METFORMIN; ANTIDIABETIC AGENT; AUTACOID; BIOLOGICAL MARKER;

ABDOMINAL AORTIC ANEURYSM; CELL VOLUME; CHONDROPROTECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; EXTRACELLULAR MATRIX; GLUCOSE TOLERANCE; GLYCATION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; THROMBOSIS; ABDOMINAL AORTA; ANIMAL; BLOOD; DISEASE EXACERBATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; LESIONS AND DEFECTS; METABOLISM; PATHOLOGY; RISK FACTOR; VASCULAR REMODELING;

ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; DILATATION, PATHOLOGIC; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; GLYCATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; OXIDATIVE STRESS; RISK FACTORS; VASCULAR REMODELING;

EID: 85048193457     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164118780799     Document Type: Review

References (68)

1. De Rango P, Farchioni L, Fiorucci B. Diabetes and abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2014; 47: 243–261
2. Sweeting MJ, Thompson SG, Brown LC. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 2012; 99: 655–665
3. Takagi H, Umemoto T,; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Diabetes and abdominal aortic aneurysm growth. Angiology 2015; 67: 513–525
4. Takagi H, Umemoto T., A contemporary meta-analysis of the association of diabetes with abdominal aortic aneurysm. Int Angiol 2015; 34: 375–382
5. Takagi H, Umemoto T,; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Negative association of diabetes with rupture of abdominal aortic aneurysm. Diab Vasc Dis Res 2016; 13: 341–347
6. Hendy K, Gunnarsson R, Cronin O. Infra-renal abdominal aortic calcification volume does not predict small abdominal aortic aneurysm growth. Atherosclerosis 2015; 243: 334–338
7. Shantikumar S, Ajjan R, Porter KE. Diabetes and the abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2010; 39: 200–207
8. Norman PE, Davis TM, Le MT. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. Connect Tissue Res 2007; 48: 125–131
9. Gnudi L, Gruden G, Viberti GF., Pathogenesis of diabetic nephropathy. In: Pickup JC, Williams G, (eds) Textbook of diabetes. Oxford: Blackwell Publishing, 2003, pp. 52.1–52.22
10. Astrand H, Ryden-Ahlgren A, Sundkvist G. Reduced aortic wall stress in diabetes mellitus. Eur J Vasc Endovasc Surg 2007; 33: 592–598
11. Jones SC, Saunders HJ, Qi W. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia 1999; 42: 1113–1119
12. Shi Q, Rafii S, Wu MH. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362–367
13. Hellenthal FA, Geenen IL, Teijink JA. Histological features of human abdominal aortic aneurysm are not related to clinical characteristics. Cardiovasc Pathol 2009; 18: 286–293
14. Death AK, Fisher EJ, McGrath KC. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263–269
15. Portik-Dobos V, Anstadt MP, Hutchinson J. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51: 3063–3068
16. Mondy JS, Anstadt MP, Franga DL. Decreased vascular matrix metalloproteinase abundance in diabetic patients with symptomatic macroangiopathy. Ethn Dis 2002; 12: S3-18–22
17. Del Prete D, Anglani F, Forino M. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 1997; 40: 1449–1454
18. Singh R, Alavi N, Singh AK. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999; 48: 2066–2073
19. Singh R, Song RH, Alavi N. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1. Exp Nephrol 2001; 9: 249–257
20. Dua MM, Miyama N, Azuma J. Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery 2010; 148: 429–435
21. Aronson D., Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003; 21: 3–12
22. Chirinos JA, Segers P, Gillebert TC. Central pulse pressure and its hemodynamic determinants in middle-aged adults with impaired fasting glucose and diabetes: the Asklepios study. Diabetes Care 2013; 36: 2359–2365
23. Norman PE, Davis WA, Coughlan MT. Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study. J Vasc Surg 2009; 50: 626–631
24. Meerwaldt R, Zeebregts CJ., Regarding ‘Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study’. J Vasc Surg 2010; 52: 535–536, author reply 536
25. Zhang F, Kent KC, Yamanouchi D. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg 2009; 250: 416–423
26. Koole D, van Herwaarden JA, Schalkwijk CG. A potential role for glycated cross-links in abdominal aortic aneurysm disease. J Vasc Surg 2017; 65: 1493.e3–1503.e3
27. de Vos LC, Boersema J, Hillebrands JL. Diverging effects of diabetes mellitus in patients with peripheral artery disease and abdominal aortic aneurysm and the role of advanced glycation end–products: ARTERY study – protocol for a multicentre cross-sectional study. BMJ Open 2017; 7: e012584
28. Kobayashi T, Osakabe T, Seyama Y., Comparison of elastolytic activity between experimental aneurysm and experimental diabetes mellitus. Biol Pharm Bull 1998; 21: 775–777
29. Grzebyk E, Knapik-Kordecka M, Piwowar A., Advanced glycation end-products and cathepsin cysteine protease in type 2 diabetic patients. Pol Arch Med Wewn 2013; 123: 364–370
30. Zhang F, Banker G, Liu X. The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res 2011; 171: 871–876
31. Golledge J, Karan M, Moran CS. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J 2008; 29: 665–672
32. Eagleton MJ., Inflammation in abdominal aortic aneurysms: cellular infiltrate and cytokine profiles. Vascular 2012; 20: 278–283
33. Kayama Y, Raaz U, Jagger A. Diabetic cardiovascular disease induced by oxidative stress. Int J Mol Sci 2015; 16: 25234–25263
34. Burke AP, Kolodgie FD, Zieske A. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004; 24: 1266–1271
35. Arapoglou V, Kondi-Pafiti A, Rizos D. The influence of diabetes on degree of abdominal aortic aneurysm tissue inflammation. Vasc Endovascular Surg 2010; 44: 454–459
36. Miyama N, Dua MM, Yeung JJ. Hyperglycemia limits experimental aortic aneurysm progression. J Vasc Surg 2010; 52: 975–983
37. Hurks R, Vink A, Hoefer IE. Atherosclerotic risk factors and atherosclerotic postoperative events are associated with low inflammation in abdominal aortic aneurysms. Atherosclerosis 2014; 235: 632–641
38. Viardot A, Grey ST, Mackay F. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology 2007; 148: 346–353
39. Haidet J, Cifarelli V, Trucco M. Anti-inflammatory properties of C-peptide. Rev Diabet Stud 2009; 6: 168–179
40. Tanaka T, Takei Y, Yamanouchi D., Hyperglycemia suppresses calcium phosphate-induced aneurysm formation through inhibition of macrophage activation. J Am Heart Assoc 2016; 5: e003062
41. Jones AG, Hattersley AT., The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013; 30: 803–817
42. Cifarelli V, Luppi P, Tse HM. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis 2008; 201: 248–257
43. Haidet J, Cifarelli V, Trucco M. C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia. Inflamm Res 2012; 61: 27–35
44. Wolf YG, Thomas WS, Brennan FJ. Computed tomography scanning findings associated with rapid expansion of abdominal aortic aneurysms. J Vasc Surg 1994; 20: 529–535, discussion 535–538
45. Dunn EJ, Ariens RA, Grant PJ., The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198–1206
46. Festa A, Williams K, Tracy RP. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 1753–1759
47. Murphy G, Atkinson S, Ward R. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 1992; 667: 1–12
48. Thompson A, Cooper JA, Fabricius M. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010; 52: 55.e2–61.e2
49. Fujimura N, Xiong J, Kettler EB. Metformin treatment status and abdominal aortic aneurysm disease progression. J Vasc Surg 2016; 64: 46.e8–54.e8
50. Vasamsetti SB, Karnewar S, Kanugula AK. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 2015; 64: 2028–2041
51. Hsu CY, Su YW, Chen YT. Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis. Cardiovasc Diabetol 2016; 15: 125
52. Golledge J, Moxon J, Pinchbeck J. Association between metformin prescription and growth rates of abdominal aortic aneurysms. Br J Surg 2017; 104: 1486–1493
53. Kristensen KL, Pottegard A, Hallas J. Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms. J Vasc Surg 2017; 66: 768.e2–774.e2
54. Jones A, Deb R, Torsney E. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 2009; 119: 3125–3132
55. Pirianov G, Torsney E, Howe F. Rosiglitazone negatively regulates c-Jun N-terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms. Atherosclerosis 2012; 225: 69–75
56. Golledge J, Cullen B, Rush C. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis 2010; 210: 51–56
57. Charolidi N, Pirianov G, Torsney E. Pioglitazone identifies a new target for aneurysm treatment: role of Egr1 in an experimental murine model of aortic aneurysm. J Vasc Res 2015; 52: 81–93
58. Motoki T, Kurobe H, Hirata Y. PPAR-γ agonist attenuates inflammation in aortic aneurysm patients. Gen Thorac Cardiovasc Surg 2015; 63: 565–571
59. Lu HY, Huang CY, Shih CM. A potential contribution of dipeptidyl peptidase-4 by the mediation of monocyte differentiation in the development and progression of abdominal aortic aneurysms. J Vasc Surg 2016; 66: 1217.e1–1226.e1
60. Kohashi K, Hiromura M, Mori Y. A dipeptidyl peptidase-4 inhibitor but not incretins suppresses abdominal aortic aneurysms in angiotensin II-infused apolipoprotein E-null mice. J Atheroscler Thromb 2015; 23: 441–454
61. van’t Hof FN, Vaucher J, Holmes MV. Genetic variants associated with type 2 diabetes and adiposity and risk of intracranial and abdominal aortic aneurysms. Eur J Hum Genet 2017; 25: 758–762
62. Maegdefessel L, Azuma J, Toh R. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 2012; 122: 497–506
63. Slusarz A, Pulakat L., The two faces of miR-29. J Cardiovasc Med (Hagerstown) 2015; 16: 480–490
64. Massart J, Sjogren RJO, Lundell LS. Altered miR-29 expression in type 2 diabetes influences glucose and lipid metabolism in skeletal muscle. Diabetes 2017; 66: 1807–1818
65. Madi HA, Riches K, Warburton P. Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and type 2 diabetic patients. Am J Physiol Cell Physiol 2009; 297: C1307–C1317
66. Choke E, Cockerill G, Wilson WR. A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 2005; 30: 227–244
67. Chai Z, Dai A, Tu Y. Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury. J Am Soc Nephrol 2013; 24: 1782–1792
68. Li J, Huynh P, Dai A. Diabetes reduces severity of aortic aneurysms depending on the presence of cell division autoantigen 1 (CDA1). Diabetes 2018; 67: 755–768